IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

Arun has over 15 years’ experience covering the Technology sector. During this time, he has worked with technology start-ups and as an equity analyst in investment banks and independent research firms. He was formerly a Technology Analyst for Canaccord Genuity, Altium Securities, Espirito Santo Investment Bank, Noble Group and Clear Capital. He has a dual Master’s degree in Financial Engineering and Industrial and Operations Engineering from the University of Michigan. He obtained his Bachelor’s degree in Mechanical Engineering from the Indian Institute of Technology, Bombay. He is also a CFA charterholder.

IPOs and Catalysts/Events

Akesobio: Trading Debut, Valuation Scenario Analysis

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

Akeso Biopharma Inc / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/akeso-biopharma-inc" target="_blank" data-smartkarma-citation="entities:28830:1" rel="noopener">Akeso Biopharma Inc (1495016D CH)</a> is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology and other therapeutic areas. Amid the extreme market volatility, it is braving the moribund IPO market by pre-marketing a Hong Kong IPO to raise $200-300 million. </p><div class="content-highlight"><p>Akesobio has strong pedigree due to a combination of credible pre-IPO investors and partnerships with leading pharma companies. The four core drug candidates which target an array of indications are AK104 (PD-1/CTLA-4), penpulimab (AK105) (PD-1), AK101 (IL-12/IL-23) and ebronucimab (AK102) (PCSK9). Overall, we believe that most of the key products have good prospects.</p></div>

Akeso Biopharma Inc (1495016D CH) is a clinical-stage biopharmaceutical company with aims to address global unmet medical needs in oncology, immunology and other therapeutic areas. Amid the extreme market volatility, it is braving the moribund IPO market by pre-marketing a Hong Kong IPO to raise $200-300 million. Akesobio has strong pedigree due to a combination of credible pre-IPO investors and partnerships with leading pharma companies. The four core drug candidates which target an array of indications are AK104 (PD-1/CTLA-4), penpulimab (AK105) (PD-1), AK101 (IL-12/IL-23) and ebronucimab (AK102) (PCSK9). Overall, we believe that most of the key products have good prospects.

Dawnrays Pharmaceutical (Holdings) (2348 HK)

Akesobio IPO Initiation: The Tough Get Going